BBIO
BridgeBio Pharma·NASDAQ
--
--(--)
--
--(--)
5.76 / 10
Netural
Fund flow metrics score 7.93/10, revealing robust fund flow characteristics. Beneficial overall, block, Small, Medium, and Extra-large trends are challenged by problematic Large signals, indicating positive capital movement. Research analyst consensus shows overwhelmingly bullish analyst consensus, demonstrating strong conviction. Current ratings: Strong Buy(33.3%), Buy(66.7%) across 3 coverage providers, supported by 3.60 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
33%
Buy
67%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-08
InstitutionTruist Securities
Times predicted3
Historical Win Rate100.0%
Is money flowing into or out of BBIO?
- BBIO holds a Bearish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.76/10 (Netural).
